Tiziana Life Sciences (TILS)

 

TILS Share PerformanceMore

52 week high240.00 25/04/17
52 week low102.05 08/06/17
52 week change -33.10 (-16.90%)
4 week volume40,250 29/06/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Tiziana enrols first patient in Phase IIa clinical trial

Tiziana Life Sciences announced the enrolment of the first patient in its Phase IIa clinical trial with milciclib, a novel inhib...

Initiation of a Phase IIa Clinical Trial

RNS Number: 4306L Tiziana Life Sciences PLC 19 July 2017 Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular Carcinoma Milciclib, a novel inhibitor of pan-CDKs, has shown clinical responses in refractory cancer patients London, 19 July, 2017 -...

Proposed changes to CLNs and Warrant Terms

RNS Number: 7751K Tiziana Life Sciences PLC 12 July 2017 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION Tiziana Life Sciences plc ("Tiziana" or "the Company") Proposed restructuring of Convertible Loan Notes and Proposed Variation of Warrant Terms London,12 July 2017 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS), a clinical stage bio...

Result of AGM

RNS Number: 5837J Tiziana Life Sciences PLC 29 June 2017 Tiziana Life Sciences plc ("Tiziana" or "the Company") Results of Annual General Meeting At the Annual General Meeting of the Company held at 10.30 a.m. on Thursday 29 June 2017 all the resolutions proposed were duly passed. Details of the proxy voting at the Annual General Meeting will be posted to t...

Appointment of Dr Kunwar Shailubhai as CEO

RNS Number: 7228H Tiziana Life Sciences PLC 12 June 2017 Tiziana Life Sciences PLC ("Tiziana" or "the Company") Tiziana Life Sciences strengthens unique research focus by appointing Dr Kunwar Shailubhai as Chief Executive Officer London, UK - 12 June, 2017 - Tiziana Life Sciences (AIM: TILS) , a clinical stage biotechnology company developing targeted dr...

NOTIFICATION OF MAJOR INTEREST IN SHARES

RNS Number: 5387H Tiziana Life Sciences PLC 08 June 2017 T R -1: N O T I F IC A T I ONOF M A JORI NT E R ESTINSH A RE S i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii TIZIANA LIFE SCIENCES PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal ...

Bcl-3 pre-clinical update and Director's dealing

RNS Number: 5190H Tiziana Life Sciences PLC 08 June 2017 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION Tiziana Life Sciences plc ("Tiziana" or "the Company") Bcl-3 pre-clinical development programme update and Director's dealing London, 8 June 2017 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS), a clinical stage biotechnology company...

2016 Annual Report and Accounts and notice of AGM

RNS Number: 7524G Tiziana Life Sciences PLC 01 June 2017 Tiziana Life Sciences plc ("Tiziana" or "the Company") 2016 Annual Report and Accounts and notice of Annual General Meeting London, 01 June 2017 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, t...

Fundamental DataMore

EPS-7.7
Dividend yield0 %

Equity Research (TILS)

equity development
Tiziana Life Sciences PLC
26/01/2015
TILS has just announced an exclusive license with Nerviano Medical Sciences (NMS) for its Phase 2 anti-cancer drug candidate, milciclib. It helps block the rampant cell division associated with...
equity development
Tiziana Life Sciences PLC
12/01/2015
Tiziana (TILS) and Novimmune S.A., a company focused on the discovery and development of antibody-based drugs to benefit patients with inflammatory, auto-immune disorders, and cancer, have announced...
equity development
Tiziana Life Sciences PLC
30/09/2014
Tiziana Life Sciences (TILS) has identified a potential 'master regulator' for metastatic breast cancer (mBC). 'Bcl-3 inhibition' would be a novel strategy for treatment,...

Latest discussion posts More

  • Top up

    Bad news this am but couldn't resist a 500 top up at 115.06.
    8-Jun-2017
    osammyboy
  • Fundraise

    Beaufort Securities's note out this morning on Research Tree: "Tiziana progressed well during the FY2015. It strengthened its portfolio by acquiring exclusive licence for both ...
    8-Jun-2016
    Simbr
  • no buying

    With sp @110 and bid @ 115 I tried buying 2500 online at Barclays. Quoted 187.4 Obviously buying is being discouraged for whatever reason
    28-Apr-2016
    osammyboy

Users' HoldingsMore

Users who hold Tiziana Life Sciences also hold..
LENOVO65%
LLOYDS GRP.30%
ROYAL BANK SCOT20%
TAYLOR WIMPEY16%
BT GROUP13%

Codes & Symbols

ISINGB00BKWNZY55
SymbolsTILS, LSE:TILS, TILS.L, TILS:LN, LON:TILS, XLON:TILS